You just read:

ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer

News provided by

ARMO BioSciences, Inc.

Mar 29, 2017, 06:00 ET